

Principal Investigator: Jonathan S. Berek, M.D.

Lay Title: A Study of Capecitabine in Women with Cervical Cancer

Study Number: GOG #128-G

UCLA IRB Number: 02-04-088

Diagnosis: Persistent or recurrent non-squamous cell carcinoma of the cervix

Description: This study is for women who have a malignant cervix tumor which has not responded to chemotherapy, surgery, radiation therapy, and/or other drugs. The purpose of this investigational study is to evaluate the effectiveness and side effects of capecitabine. Capectiabine is being evaluated to see if it is effective in the treatment of cervical cancer.

Eligibility:

- Persistent or recurrent non-squamous cell carcinoma of the cervix.
- Tumor that can be measured by CT scan, MRI, Physical Exam, etc.
- Patients must have had one prior systemic chemotherapy regimen
- Patients must not have received more than one previous cytotoxic chemotherapy regimen
- Patients are allowed to receive, but are not required to receive, one additional non-cytotoxic regimen
- Non-cytotoxic (biologic or cytostatic) agents include but are not limited to monoclonal antibodies, cytokines, and small-molecule inhibitors of signal transduction.
- Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of the other malignancy being present within the last 5 years.

Contact Information:

Tery Schooler

Phone: (310) 206-5161

E-mail: Tschooler@mednet.ucla.edu

OR

Monica Rocha

Phone: (310) 794-9095

E-mail: MRocha@mednet.ucla.edu

Consent Form Date of Preparation: July 29, 2003

Consent Form IRB Approval Stamp: August 19, 2003

Last Website Update: September 24, 2003